Inside Washington: Reshaping Biotech Drug Development

June 15, 2003

Jill Wechsler

Jill Wechsler

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.

BioPharm International, BioPharm International-06-01-2003, Volume 16, Issue 6

by Jill Wechsler, BioPharm International FDA is examining policy options for incorporating genomic information into the regulatory process while encouraging manufacturers to share pharmacogenomic research.

Related Content:

Guest Interview: A Strong Dose of Reality: Visiting with Cynthia Robbins-Roth

Collaborating Across the Extended Pharmaceutical Enterprise: How Sharing Information Leads to Process Enablement

Sialylation Levels Influence Oligosaccharide Quantitation: Analyzing Response Variability Using High-pH Anion-Exchange Chromatography and Pulsed Amperometric Detection